

Supplementary material has been published as submitted. It has not been copyedited or typeset by Acta Oncologica.

Supplementary Table 1. Overall survival (OS) by class of first line therapy, histology, and ECOG PS

Class of therapy	Nonsquamous		Squamous	
	Overall	ECOG PS 0-1	Overall	ECOG PS 0-1
PD-(L)1 inhibitor monotherapy				
Patients	387	308	113	85
Events	246	183	78	61
Median (95% CI)	15.2 (11.9 - 18.6)	18.6 (14.8 - 23.4)	13 (10.5 - 17.7)	13.3 (10.5 - 17.7)
12 months	54.2 (49.5 - 59.4)	59.7 (54.4 - 65.4)	53.9 (45.5 - 64)	54.1 (44.5 - 65.8)
24 months	38 (33.2 - 43.6)	43.2 (37.7 - 49.6)	29.9 (21.9 - 40.8)	29.2 (20.5 - 41.7)
36 months	27.4 (22.1 - 34)	29.9 (23.7 - 37.7)	25 (17.2 - 36.3)	23.2 (14.8 - 36.3)
PD-(L)1 inhibitor combination				
Patients	116	102	20	17
Events	60	48	6	4
Median (95% CI)	17.1 (13.1 - NA)	24 (14.3 - NA)	NE	NE
12 months	61.1 (52.9 - 70.7)	62.7 (53.9 - 72.8)	NE	NE
24 months	42.8 (32.8 - 55.7)	48.8 (38.1 - 62.4)	NE	NE
36 months	19.2 (4.6 - 80.1)	22 (5.3 - 91.1)	NE	NE
Platinum-based chemotherapy combination				
Patients	841	605	224	161
Events	716	497	190	135
Median (95% CI)	7.8 (7.2 - 8.5)	9.5 (8.5 - 10.5)	9.9 (7.8 - 11.5)	11.7 (10 - 13.9)
12 months	34.5 (31.4 - 37.8)	40.8 (37.1 - 44.9)	42.4 (36.4 - 49.4)	49.7 (42.5 - 58)
24 months	18.9 (16.3 - 21.8)	22.7 (19.5 - 26.4)	24 (18.9 - 30.5)	26.6 (20.4 - 34.7)
36 months	13.1 (10.8 - 15.8)	15.7 (12.9 - 19.2)	12.1 (8.1 - 18.2)	12.7 (8 - 20.1)